Immix Biopharma, Inc.
Immix Biopharma is a clinical-stage biopharmaceutical company developing chimeric antigen receptor T-cell therapies for light chain amyloidosis and other serious diseases. Its lead candidate, NXC-201, is a CAR-T therapy targeting BCMA and is being evaluated in U.S. and ex-U.S. clinical trials for relapsed or refractory AL amyloidosis. Immix also pursues NXC-201 in other serious diseases and has additional preclinical candidates. Its N-GENIUS platform includes cell-therapy design and data tools, EXPAND technology, and a binding-scaffold generation engine. Immix is developing its candidates for potential treatment and sale, and relies on third-party contract manufacturers to produce them for preclinical and clinical testing and, if approved, commercial manufacture. It also holds a California grant supporting NXC-201’s clinical development. Immix Biopharma is headquartered in Los Angeles, California.
No SEC Form 4 filings for $IMMX in the last 30 days.
See all $IMMX insider activity →Immix Biopharma reported $340.9M in cash and equivalents as of Q3 2026, with $15.9M in operating expenses. The company expects its runway to extend into mid-2028, according to its press release.
Immix Biopharma, Inc. (IMMX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress – Following positive NEXICART-2 clinical update, commercial launch preparation continues with commercial site activation activities, strengthened team, and provider and paye
Immix Biopharma (IMMX) will present interim clinical trial results for NXC-201 at the ASH 2026 meeting. The trial, NEXICART-2, focuses on relapsed/refractory AL amyloidosis, a disease with a growing U.S. patient population. Immix's NXC-201 has received FDA and EMA designations. The amyloidosis market is projected to reach $6.6B in 2026, per Grand View Research.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning IMMX (Immix Biopharma, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent IMMX coverage spans corporate actions, technology and earnings.
The cash runway to mid‑2028 provides financial stability, likely supporting the stock price.
Positive trial data and strong cash position suggest near‑term upside potential.
First disclosure of interim safety and efficacy data for a breakthrough‑therapy CAR‑T candidate in relapsed/refractory AL amyloidosis.
Analyst upgrade and positive trial data suggest significant upside potential.
The capital raise provides significant funding for clinical development but introduces dilution.
AlphAI scores every news story that mentions IMMX with an AI model for sentiment and relevance, and aggregates insider trades from Immix Biopharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Immix Biopharma reported $340.9M in cash and equivalents as of Q3 2026, with $15.9M in operating expenses. The company expects its runway to extend into mid-2028, according to its press release.
Immix Biopharma, Inc. (IMMX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress – Following positive NEXICART-2 clinical update, commercial launch preparation continues with commercial site activation activities, strengthened team, and provider and paye
Immix Biopharma (IMMX) will present interim clinical trial results for NXC-201 at the ASH 2026 meeting. The trial, NEXICART-2, focuses on relapsed/refractory AL amyloidosis, a disease with a growing U.S. patient population. Immix's NXC-201 has received FDA and EMA designations. The amyloidosis market is projected to reach $6.6B in 2026, per Grand View Research.
Morgan Stanley initiated Immix Biopharma (IMMX) with an overweight rating and $20 target. The stock is up 168% in a year but down 5.4% recently. Analysts see strong potential in its AL amyloidosis treatment, with high response rates in trials. Q2 2026 earnings showed a wider-than-expected loss. Multiple analysts raised price targets, citing pipeline progress and market potential.
Immix Biopharma (IMMX) closed a $125M offering of 11.36M common shares at $11 each, netting $117.1M after expenses. Proceeds will fund NXC-201 development and general corporate purposes. J.P. Morgan led the offering.
Immix Biopharma, Inc. (IMMX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock LOS ANGELES, CA, September 29, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis
Immix Biopharma (IMMX) reported an 89% complete response rate in a Phase 2 study of NXC-201 for treating AL amyloidosis, with potential to reach 98%. The study, involving 45 patients, showed no relapses or severe side effects. NXC-201 has received FDA and EMA designations. IMMX stock is down 6.71% at $10.70.
Immix Biopharma, Inc. (IMMX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosi
Mizuho analyst Graig Suvannavejh named Immix Biopharma (IMMX) as his top September pick, raising the price target to $26 from $15. The upgrade is based on the potential of NXC-201, a drug for relapsed/refractory AL amyloidosis, with projected peak global revenue of $1 billion. Immix shares have gained 133% year-to-date, outperforming the broader biotech sector. The company reported a net loss of $0.18 per share for Q2 2026.
The article says convicted fugitive former doctor Ronald Fischer, 70, appeared in Rhode Island court under an alias, after being arrested in July 2024 while working as Chief Medical Officer for Immix Biopharma. It reports Immix filed an SEC Form 8-K stating “Richard Graydon” was terminated and is no longer with the company, and that shareholder law firms are investigating hiring practices.
